THTX
Theratechnologies Inc
$
3.195
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
3.195
Open
3.195
VWAP
3.20
Vol
1.47K
Mkt Cap
63.91M
Low
3.195
Amount
4.69K
EV/EBITDA(TTM)
17.33
Total Shares
45.98M
EV
180.76M
EV/OCF(TTM)
25.69
P/S(TTM)
1.88
Theratechnologies Inc. is a Canada-based specialty biopharmaceutical company focused on the commercialization of innovative therapies. The Company offers prescription products for individuals with human immunodeficient virus (HIV) in the United States and its pipeline is focused on specialized therapies designed to address unmet medical needs in both HIV and oncology. It markets two HIV products, namely EGRIFTA SV and Trogarzo; and has research programs in HIV and oncology. EGRIFTA SV is the therapy for reducing excess abdominal fat in HIV-infected adults with lipodystrophy. Trogarzo injection is used with other antiretrovirals to treat HIV-1 infection in heavily treatment-experienced adults with multidrug resistant HIV-1 who are failing their current regimen. Its pipeline includes Donidalorsen and Olezarsen, and the SORT1+ oncology platform. The Company is also focusing on tesamorelin life-cycle management in lipodystrophy.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q1
FY2025Q4
FY2025Q3
21.12M
+10.04%
--
--
22.04M
-11.6%
--
--
19.68M
-12.53%
--
--
Estimates Revision
The market is revising No Change the revenue expectations for Theratechnologies Inc. (THTX) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 22.41%.
Revenue Estimates for FY2025
No Change
0.00%
In Past 3 Month
Stock Price
Go Up
+22.41%
In Past 3 Month
1 Analyst Rating
-20.19% Downside
Wall Street analysts forecast THTX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for THTX is 2.55 USD with a low forecast of 2.55 USD and a high forecast of 2.55 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
1 Hold
0 Sell
Hold
-20.19% Downside
Current: 3.195
Low
2.55
Averages
2.55
High
2.55
-20.19% Downside
Current: 3.195
Low
2.55
Averages
2.55
High
2.55
JonesResearch
Buy
to
Hold
downgrade
$3.01
2025-07-03
Reason
JonesResearch
Price Target
$3.01
2025-07-03
downgrade
Buy
to
Hold
Reason
JonesResearch downgraded Theratechnologies to Hold from Buy after the company announced an agreement with CB Biotechnology, an affiliate of Future Pak, to be acquired for $3.01 per share in cash plus one contingent value right per share for additional aggregate cash payments of up to $1.19 per CVR if certain milestones are achieved.
Jones Trading
Justin Walsh
Strong Buy
to
Hold
Downgrades
n/a
2024-10-11
Reason
Jones Trading
Justin Walsh
Price Target
n/a
2024-10-11
Downgrades
Strong Buy
to
Hold
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Theratechnologies Inc (THTX.O) is 79.84, compared to its 5-year average forward P/E of 7.64. For a more detailed relative valuation and DCF analysis to assess Theratechnologies Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
7.64
Current PE
79.84
Overvalued PE
46.83
Undervalued PE
-31.55
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
75.45
Current EV/EBITDA
9.48
Overvalued EV/EBITDA
426.12
Undervalued EV/EBITDA
-275.22
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Fair
5Y Average PS
1.88
Current PS
1.76
Overvalued PS
3.07
Undervalued PS
0.69
Financials
Annual
Quarterly
FY2025Q2
YoY :
-19.48%
17.73M
Total Revenue
FY2025Q2
YoY :
-116.58%
-545.00K
Operating Profit
FY2025Q2
YoY :
-552.08%
-4.46M
Net Income after Tax
FY2025Q2
YoY :
-550.00%
-0.09
EPS - Diluted
FY2025Q2
YoY :
-792.46%
12.40M
Free Cash Flow
FY2025Q2
YoY :
-7.37%
73.50
Gross Profit Margin - %
FY2025Q2
YoY :
-20.48%
-3.65
FCF Margin - %
FY2025Q2
YoY :
-661.83%
-25.17
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
THTX News & Events
Events Timeline
2025-07-09 (ET)
2025-07-09
07:34:15
Theratechnologies withdraws FY25 revenue, adjusted EBITDA guidance
2025-07-09
07:33:52
Theratechnologies reports Q2 revenue $17.7M vs. $22M last year
2025-07-03 (ET)
2025-07-03
05:50:30
Theratechnologies to be acquired by CB Biotechnology for $254M
Sign Up For More Events
Sign Up For More Events
News
4.5
07-09BenzingaDow Tumbles Over 150 Points Amid Trump Tariffs: Investor Sentiment Declines, Fear Index Moves To 'Greed' Zone
3.0
07-09BenzingaAZZ, Aehr Test Systems And 3 Stocks To Watch Heading Into Wednesday
9.5
07-03NewsfilterTheratechnologies to Announce Second Quarter 2025 Financial Results
Sign Up For More News
People Also Watch
WHLRL
Wheeler Real Estate Investment Trust Inc
110.360
USD
+9.09%
URG
Ur-Energy Inc
1.195
USD
-2.05%
TRMD
Torm PLC
18.495
USD
-3.82%
TPGXL
TPG Operating Group II, L.P. 6.950% Fixed-Rate Junior Subordinated Notes due 2064
25.630
USD
0.00%
USAS
Americas Gold and Silver Corporation
1.075
USD
-1.38%
WHFCL
WhiteHorse Finance Inc
25.570
USD
0.00%
TU
Telus Corp
15.975
USD
-0.65%
UBS
UBS Group AG
38.795
USD
-1.88%
UROY
Uranium Royalty Corp
2.615
USD
-0.19%
FAQ
What is Theratechnologies Inc (THTX) stock price today?
The current price of THTX is 3.195 USD — it has increased 0 % in the last trading day.
What is Theratechnologies Inc (THTX)'s business?
What is the price predicton of THTX Stock?
What is Theratechnologies Inc (THTX)'s revenue for the last quarter?
What is Theratechnologies Inc (THTX)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Theratechnologies Inc (THTX)'s fundamentals?
How many employees does Theratechnologies Inc (THTX). have?